DILD patients who received R-CHOP (29 cases) underwent the most CHT regimens, accounting for 10.5% of all those undergoing R-CHOP, which is consistent with Zhou research.[16] Generally, R-CHOP is mainly used to treat diffuse large B-cell lymphoma; however, it is difficult to distinguish a single DILD from a comprehensive DILD. Here, DDIT3 is linked to diffuse large B-cell lymphoma.